Skip to main content

Table 5 One-way SA results

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Parameters Base case values One-way SA Values Incremental costs Incremental QALY ICUR (€/QALY gained)
Non prophylaxis Palivizumab Non- prophylaxis Palivizumab
Number of palivizumab injections per RSV season 3.88 5 €1,983.67 0.0731 27,152.79
Risk of ICU admission 17.80% 17.80% 30.00% 11.10% €1,370.71 0.0737 18,592.52
In-hospital mortality 2.33% 2.33% 0.13% 0.09% €1,438.90 0.0725 19,836.81
Proportion of patients that experience emergency visit prior to hospital admission 100.00% 50.00% €1,440.49 0.0731 19,717.70
Hospital related costs* (+/−50%) €3,031.30 +50.00% (€4.546,95) €1,354.88 0.0731 18,545.80
−50.00% (€1515.65) €1,523.18 0.0731 20,849.55
Direct recurrent wheezing management costs (+/−50%) €749.57 +50.00% (€1124.36) €1,299.30 0.0731 17,785.09
−50.00% (€.374.79) €1,578.76 0.0731 21,610.25
Annual discount rate Costs Benefits Costs Benefits  
3.0% 0.0% €1,415.22 0.0799 17,704.00
5.0% €1,453.22 0.0690 21,071.19
3.0% 1.50% €1,439.03 0.0764 18,841.25
  1. ICU: intensive care unit; ICUR: incremental cost-utility ratio; QALY quality adjusted life years, RSV respiratory syncytial virus, SA sensitivity analysis
  2. *Hospital related costs included emergency visit prior hospitalization cost, hospital and ICU admission costs